Haisco Pharmaceutical Group (002653.SZ): Obtained acceptance notice for the IND application of innovative drug HSK60002

Haisco Pharmaceutical Group (002653.SZ) announced that it has recently received a "Notice of Acceptance" from the National Medical Products Administration for its internally developed innovative drug HSK60002 tablets, which are intended for domestic production for the registration clinical trial application for the treatment of inflammatory diseases. It is reported that preclinical research data show that HSK60002 exhibits significant efficacy in relevant animal models with a clear mechanism of action. Based on existing results, HSK60002 has clear development value and good potential for translation, and is expected to provide a safe and effective new treatment option for clinical patients.